ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för BKM120. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

21 träffar

Bibliografisk träff 2013-02-12

Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.

Figlin RA, Kaufmann I, Brechbiel J.

Int J Cancer · research support, non-u.s. gov't; review; journal article · DOI 10.1002/ijc.28023

Bibliografisk träff 2013-01-15

The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro.

Amrein L, Shawi M, Grenier J, Aloyz R, Panasci L.

Int J Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/ijc.27989

Bibliografisk träff 2013-01-08

PAK1 mediates resistance to PI3K inhibition in lymphomas.

Walsh K, McKinney MS, Love C, Liu Q, Fan A, Patel A, Smith J, Beaven A, Jima DD, Dave SS.

Clin Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-12-1060

Bibliografisk träff 2012-08-22

Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.

Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM.

Cancer Discov · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/2159-8290.cd-11-0336

Bibliografisk träff 2012-08-22

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J.

Cancer Discov · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1158/2159-8290.cd-11-0348

Bibliografisk träff 2012-07-07

The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.

Ren H, Chen M, Yue P, Tao H, Owonikoko TK, Ramalingam SS, Khuri FR, Sun SY.

Cancer Lett · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.canlet.2012.06.018

Bibliografisk träff 2012-06-21

Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor.

Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano ML, Grosso V, Stivani V, Antognoli A, Lamolinara A, Landuzzi L, di Tomaso E, Iezzi M, De Giovanni C, Lollini PL.

PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0039626

Bibliografisk träff 2012-06-08

3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.

Kelly CJ, Hussien K, Muschel RJ.

Nucl Med Biol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.nucmedbio.2012.04.006

Bibliografisk träff 2012-05-31

Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.

Brachmann SM, Kleylein-Sohn J, Gaulis S, Kauffmann A, Blommers MJ, Kazic-Legueux M, Laborde L, Hattenberger M, Stauffer F, Vaxelaire J, Romanet V, Henry C, Murakami M, Guthy DA, Sterker D, Bergling S, Wilson C, Brümmendorf T, Fritsch C, Garcia-Echeverria C, Sellers WR, Hofmann F, Maira SM.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-11-1021

Bibliografisk träff 2012-04-29

Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.

Mueller A, Bachmann E, Linnig M, Khillimberger K, Schimanski CC, Galle PR, Moehler M.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1007/s00280-012-1869-z

Bibliografisk träff 2012-04-29

Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma.

Kim S, Dodd RD, Mito JK, Ma Y, Kim Y, Riedel RF, Kirsch DG.

Sarcoma · research-article; journal article · DOI 10.1155/2012/680708

Bibliografisk träff 2012-02-15

Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.

Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM, Hackl W, Camp R, Kluger HM, Chao HH.

PLoS One · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0031331

Bibliografisk träff 2011-12-30

Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.

Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li H, Lin H, Lan Y, Liu Z, He J, Hong S, Thomas S, Shah J, Baladandayuthapani V, Kwak LW, Yi Q.

J Mol Med (Berl) · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1007/s00109-011-0849-9

Bibliografisk träff 2011-12-21

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.

Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chène P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, García-Echeverría C, Sellers WR, Voliva CF.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-11-0474

Bibliografisk träff 2011-12-12

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, Goldbrunner M, Baselga J.

J Clin Oncol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1200/jco.2011.36.1360

Bibliografisk träff 2011-12-08

NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.

Park E, Park J, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.

Int J Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.3892/ijo.2011.1290

Bibliografisk träff 2011-11-07

Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.

Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, Garcia-Echevrria C, Maira SM, Yung WK.

Clin Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-11-1558

Bibliografisk träff 2011-10-31

Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.

Gallagher EJ, Fierz Y, Vijayakumar A, Haddad N, Yakar S, LeRoith D.

Oncogene · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/onc.2011.495

Bibliografisk träff 2011-07-20

ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.

Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, González-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL.

Cancer Discov · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/2159-8290.cd-11-0101

Bibliografisk träff 2011-03-01

Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.

Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ.

Breast Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1186/bcr2833

Bibliografisk träff 2010-12-01

Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.

Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P, Kluger HM.

Clin Cancer Res · research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-10-1490